Past breakthroughs in endovascular and thrombolytic therapy are now being refined to benefit more patients and more stroke types, explains an interventional neurologist in our latest podcast episode.
Cleveland Clinic just implemented an enterprise-wide change in its preferred thrombolytic for acute stroke. We share the rationale and logistics behind the change and what we hope to learn about tenecteplase moving forward.
An NIH grant will help Cleveland Clinic researchers determine whether the novel dual-action agent can safely lengthen the thrombolytic time window in ischemic stroke and protect against reperfusion injury.
A study on Cleveland Clinic’s mobile stroke unit reveals one characteristic that seems to particularly drive early IV thrombolysis delivery.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Practice may not make perfect in healthcare, but it can sure make for greater efficiency and effectiveness. This study of our mobile stroke unit’s evolution over three years is a case in point.
A Cleveland Clinic study presented at the 2018 International Stroke Conference suggests these units may help bypass interhospital transfers for patients requiring thrombectomy.
The answer is yes, according to a new national database analysis, but the differences are limited and fairly focused on promptness of reperfusion therapy.
First-line therapy for most patients with DVT should remain anticoagulation without pharmacomechanical thrombolysis, suggests the multicenter ATTRACT trial.
Which patients with submassive embolism would benefit from thrombolysis, and which patients require only anticoagulant therapy? The answer lies in finding the balance between the potential benefit of thrombolytic therapy — preventing death or hemodynamic collapse — and the numerically low but potentially catastrophic risk of intracranial bleeding.